Literature DB >> 2341717

Relative inefficiency of soluble recombinant CD4 for inhibition of infection by monocyte-tropic HIV in monocytes and T cells.

P J Gomatos1, N M Stamatos, H E Gendelman, A Fowler, D L Hoover, D C Kalter, D S Burke, E C Tramont, M S Meltzer.   

Abstract

Macrophages are major viral reservoirs in the brain, lungs, and lymph nodes of HIV-infected patients. But not all HIV isolates infect macrophages. The molecular basis for this restrictive target cell tropism and the mechanisms by which HIV infects macrophages are not well understood: virus uptake by CD4-dependent and -independent pathways have both been proposed. Soluble rCD4 (sCD4) binds with high affinity to gp 120, the envelope glycoprotein of HIV, and at relatively low concentrations (less than 1 microgram/ml) completely inhibits infection of many HIV strains in T cells or T cell lines. HTLV-IIIB infection of the H9 T cell line was completely inhibited by prior treatment of virus with 10 micrograms/ml sCD4: no p24 Ag or HIV-induced T cell syncytia were detected in cultures of H9 cells exposed to 1 x 10(4) TCID50 HTLV-IIIB in the presence of sCD4. Under identical conditions and at a 100-fold lower viral inoculum, 10 micrograms/ml sCD4 had little or no effect on infection of monocytes by any of six different HIV isolates by three different criteria: p24 Ag release, virus-induced cytopathic effects, and the frequency of infected cells that express HIV-specific mRNA. At 10- to 100-fold higher concentrations of sCD4, however, infection was completely inhibited. Monoclonal anti-CD4 also prevented infection of these same viral isolates in monocytes. The relative inefficiency of sCD4 for inhibition of HIV infection in monocytes was a property of the virion, not the target cell: HIV isolates that infect both monocytes and T cells required similarly high levels of sCD4 (100 to 200 micrograms/ml) for inhibition of infection. These data suggest that the gp120 of progeny HIV derived from macrophages interacts with sCD4 differently than that of virions derived from T cells. For both variants of HIV, however, the predominant mechanism of virus entry for infection is CD4-dependent.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2341717

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.

Authors:  P Westervelt; H E Gendelman; L Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

2.  Antibody to adhesion molecule LFA-1 enhances plasma neutralization of human immunodeficiency virus type 1.

Authors:  M B Gomez; J E Hildreth
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

3.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.

Authors:  J P Moore; J A McKeating; Y X Huang; A Ashkenazi; D D Ho
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody.

Authors:  J S McDougal; M S Kennedy; S L Orloff; J K Nicholson; T J Spira
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

Review 5.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

6.  Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4.

Authors:  W A O'Brien; I S Chen; D D Ho; E S Daar
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

7.  Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

Authors:  N Sullivan; Y Sun; J Li; W Hofmann; J Sodroski
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

8.  Mechanisms of immune activation of human immunodeficiency virus in monocytes/macrophages.

Authors:  R D Schrier; J A McCutchan; C A Wiley
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

9.  Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1.

Authors:  D Kabat; S L Kozak; K Wehrly; B Chesebro
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

10.  Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.

Authors:  Reem Berro; Rogier W Sanders; Min Lu; Per J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.